Relief Therapeutics Secures FDA Rare Pediatric Disease Designation for RLF-TD011

An announcement from RELIEF THERAPEUTICS Holding ( (CH:RLF) ) is now available.

Relief Therapeutics has received the FDA’s Rare Pediatric Disease designation for its product RLF-TD011, aimed at treating epidermolysis bullosa (EB), a rare genetic skin disorder. This designation highlights the potential of RLF-TD011 to advance EB wound care by offering a novel treatment option that modulates the wound microbiome and reduces pathogenic colonization. The designation may also allow Relief to receive a Priority Review Voucher, which could expedite FDA review for future marketing applications, potentially enhancing the company’s market position and offering significant benefits to stakeholders.

More about RELIEF THERAPEUTICS Holding

Relief Therapeutics Holding SA is a commercial-stage biopharmaceutical company based in Geneva, Switzerland. The company specializes in developing innovative treatments for rare and debilitating diseases, with a focus on drug delivery systems and drug repurposing. Relief’s clinical pipeline targets unmet medical needs in rare dermatological, metabolic, and respiratory conditions. The company is listed on the SIX Swiss Exchange and quoted in the U.S. on OTCQB.

Average Trading Volume: 23,719

Current Market Cap: CHF26.66M

For an in-depth examination of RLF stock, go to TipRanks’ Stock Analysis page.